Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
- Associated Therapies
- -
Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2020-09-02
- Target Recruit Count
- 60
- Registration Number
- NCT03288454
- Locations
- 🇺🇸
Frontage Clinical Services Inc., Secaucus, New Jersey, United States
FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty
- Conditions
- Interventions
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 813
- Registration Number
- NCT03276143
- Locations
- 🇱🇹
Republican Vilnius University Hospital, Vilnius, Lithuania
🇵🇱Wojewódzki Szpital Zespolony, Kielce, Poland
🇵🇱Szpital Specjalistyczny im. Rydygiera, Krakow, Poland
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 2760
- Registration Number
- NCT03266783
- Locations
- 🇮🇪
The Royal College of Surgeons in Ireland/Mater Misericordiae University Hospital, Dublin, Ireland
🇨🇦St. Mary's Hospital, Montreal, Quebec, Canada
🇨🇦Alberta Health Sciences, Edmonton, Alberta, Canada
Medical Need of OAC Reversal
- Conditions
- Interventions
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53969
- Registration Number
- NCT03254147
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan
Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury
- Conditions
- Interventions
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 8
- Registration Number
- NCT03200613
- Locations
- 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 1015
- Registration Number
- NCT03192215
- Locations
- 🇺🇸
VA Greater Los Angeles - West LA VA Medical Center, Los Angeles, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Grady Memorial, Atlanta, Georgia, United States
A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage
- Conditions
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36000
- Registration Number
- NCT03189069
Start or STop Anticoagulants Randomised Trial (SoSTART)
- Conditions
- Interventions
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 203
- Registration Number
- NCT03153150
- Locations
- 🇬🇧
Frimley Park Hospital, Frimley, United Kingdom
🇬🇧Gloucestershire Royal Hospital, Gloucester, United Kingdom
🇬🇧Pinderfields Hospital, Wakefield, United Kingdom
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
- Conditions
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 176
- Registration Number
- NCT03139487
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Use of Direct Oral Anticoagulants in UK
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 31336
- Registration Number
- NCT03119116
- Locations
- 🇬🇧
Many Locations, Multiple Locations, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.